Skip to main content

ALS: Challenges and New Advances

Guest Editors:
Philip Wong:
John Hopkins University School of Medicine, USA
Wilfried Rossoll: Mayo Clinic Florida, USA

Submission Status: Closed

Molecular Neurodegeneration is presenting a new Collection on "ALS: Challenges and New Advances".

Image credit: geralt / PixaBay

About the collection

The past few years have seen great conceptual and methodological advances in our understanding of disease mechanisms behind amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) disease spectrum. The aim for this 'Amyotrophic Lateral Sclerosis: Challenges and New Advances' review series is to promote in-depth discussions on exciting new developments in the field that may best facilitate our endeavors to fight the disease. The first article in this series, “Advances in sequencing technologies for amyotrophic lateral sclerosis research”, describes how novel long-read sequencing platforms are being used to uncover the contribution of repeat expansions and other types of structural variation. These emerging technologies may help explain missing heritability in ALS and aid our understanding of this challenging disease. Future contributions in this series will address the role of nuclear-import receptors in regulating pathological phase transitions in ALS, the need for better mouse models of ALS, the contribution of altered axonal functions of TDP-43 to early NMJ disruption in ALS, the role of TDP-43 dependent cryptic exon inclusion in ALS pathobiology, and emerging biomarkers to facilitate ALS recruitment and therapy development. As the field advances, we envision that other relevant topics would be included in this series.

  1. Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the loss of upper and lower motor neurons. Presently, three FDA-approved drugs are available to help slow functional de...

    Authors: Katherine E. Irwin, Udit Sheth, Philip C. Wong and Tania F. Gendron
    Citation: Molecular Neurodegeneration 2024 19:9
  2. Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are fatal neurodegenerative disorders on a disease spectrum that are characterized by the cytoplasmic mislocalization and aberrant phase tr...

    Authors: Bilal Khalil, Miriam Linsenmeier, Courtney L. Smith, James Shorter and Wilfried Rossoll
    Citation: Molecular Neurodegeneration 2024 19:8
  3. Axon degeneration and Neuromuscular Junction (NMJ) disruption are key pathologies in the fatal neurodegenerative disease Amyotrophic Lateral Sclerosis (ALS). Despite accumulating evidence that axons and NMJs a...

    Authors: Ariel Ionescu, Topaz Altman and Eran Perlson
    Citation: Molecular Neurodegeneration 2023 18:35
  4. Amyotrophic lateral sclerosis is a complex disorder most of which is ‘sporadic’ of unknown origin but approximately 10% is familial, arising from single mutations in any of more than 30 genes. Thus, there are ...

    Authors: Elizabeth M.C. Fisher, Linda Greensmith, Andrea Malaspina, Pietro Fratta, Michael G. Hanna, Giampietro Schiavo, Adrian M. Isaacs, Richard W. Orrell, Thomas J. Cunningham and Abraham Acevedo Arozena
    Citation: Molecular Neurodegeneration 2023 18:30
  5. TDP-43 is an RNA-binding protein with a crucial nuclear role in splicing, and mislocalises from the nucleus to the cytoplasm in a range of neurodegenerative disorders. TDP-43 proteinopathy spans a spectrum of ...

    Authors: Puja R. Mehta, Anna-Leigh Brown, Michael E. Ward and Pietro Fratta
    Citation: Molecular Neurodegeneration 2023 18:16

Submission Guidelines

Back to top

Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via the submission system. During the submission process you will be asked whether you are submitting to an Article Collection, please select "ALS: Challenges and New Advances" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.